A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
| Status: | Completed |
|---|---|
| Conditions: | Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | July 2008 |
| End Date: | May 2014 |
An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
The purpose of this study is to evaluate the long-term effects of orally administered
SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001
study.
SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001
study.
SAR302503 (TG101348) is a potent small molecule inhibitor of Janus kinase 2 (JAK2). This is
an extension study for a first-in-man, dose escalation study (MF-TG101348-001). The safety,
tolerability and clinical activity of SAR302503 (TG101348) in subjects with myelofibrosis
will be evaluated.
an extension study for a first-in-man, dose escalation study (MF-TG101348-001). The safety,
tolerability and clinical activity of SAR302503 (TG101348) in subjects with myelofibrosis
will be evaluated.
Inclusion Criteria:
- Completion of MF-TG101348-001 study
- Diagnosis of myelofibrosis
- At least 18 years of age
Exclusion Criteria:
- Any acute or chronic medical abnormality that may increase the risk associated with
study participation
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials